Page 2 - Cell Death News Today

The Backstory:  As it stands today,when one of the National Institutes of Health (NIH) provides the funding for a scientific research project, and those results are published, they must be made freely available to public, within a set period of time.  The reasoning behind this requirement is that taxpayers funded everything about the research except for the final publication, and so they have already paid for access.

WEST LAFAYETTE — A breakthrough in the understanding of the relationship between a naturally occurring enzyme and the liver cancer drug sorafenib could improve the effectiveness of the drug, which

WEST LAFAYETTE — A breakthrough in the understanding of the relationship between a naturally occurring enzyme and the liver cancer drug sorafenib could improve the effectiveness of the drug, which currently prolongs the life of liver cancer patients for only two to three months. A study of the r ...

Decades of research have characterized diverse immune cells surveilling the CNS. More recently, the discovery of osseous channels (so-called ‘skull channels’) connecting the meninges with the skull and vertebral bone marrow has revealed a new layer of complexity in our understanding of neuroimmune interactions. Here we discuss our current understanding of skull and vertebral bone marrow anatomy, its contribution of leukocytes to the meninges, and its surveillance of the CNS. We explo...

Salicylate, a compound found in willow

Inflammation can cause a host of issues if not treated properly. That's why we bring you the best CBD for anti-inflammatory issues in 2023!

Researchers at the University of California, Davis, have discovered specific antibodies that, when attached to Fas receptors on cancer tumour blood vessels, trigger programmed cell death

Scientists have figured out a way to detonate the 'doors' that lead to the heart of cancerous tumors, blowing them wide open for drug treatments.

The receptor, called CD95, could improve the effectiveness of immune-based therapies.

Aspirin has been shown to reduce colorectal cancer risk and inhibit cancer progression. A new study has revealed the molecular mechanisms behind these effects.